|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACY3 |
Gene summary for ACY3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACY3 | Gene ID | 91703 |
| Gene name | aminoacylase 3 | |
| Gene Alias | ACY-3 | |
| Cytomap | 11q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A024R5L2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 91703 | ACY3 | Pat01-B | Human | Stomach | GC | 1.50e-25 | 5.67e-01 | 0.5754 |
| 91703 | ACY3 | Pat03-B | Human | Stomach | GC | 1.16e-16 | 3.92e-01 | 0.3693 |
| 91703 | ACY3 | Pat05-B | Human | Stomach | GC | 1.99e-04 | 2.58e-01 | -0.0353 |
| 91703 | ACY3 | Pat06-B | Human | Stomach | GC | 2.80e-02 | 1.05e-01 | -0.1961 |
| 91703 | ACY3 | Pat25-A | Human | Stomach | CAG with IM | 2.87e-04 | 9.25e-02 | -0.1648 |
| 91703 | ACY3 | SIM_1 | Human | Stomach | SIM | 2.19e-06 | 3.38e-01 | 0.3573 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACY3 | SNV | Missense_Mutation | rs780801563 | c.928N>A | p.Ala310Thr | p.A310T | Q96HD9 | protein_coding | tolerated(0.48) | benign(0.005) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACY3 | deletion | Frame_Shift_Del | c.544delC | p.Gln182SerfsTer14 | p.Q182Sfs*14 | Q96HD9 | protein_coding | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |||
| ACY3 | deletion | Frame_Shift_Del | novel | c.236delA | p.Asn79IlefsTer12 | p.N79Ifs*12 | Q96HD9 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| ACY3 | SNV | Missense_Mutation | rs754555869 | c.28N>T | p.Pro10Ser | p.P10S | Q96HD9 | protein_coding | deleterious(0) | benign(0.39) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ACY3 | SNV | Missense_Mutation | c.298N>A | p.Leu100Met | p.L100M | Q96HD9 | protein_coding | deleterious(0.01) | probably_damaging(0.91) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ACY3 | SNV | Missense_Mutation | rs764927492 | c.700N>G | p.Thr234Ala | p.T234A | Q96HD9 | protein_coding | tolerated(0.18) | benign(0.006) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ACY3 | SNV | Missense_Mutation | novel | c.329N>G | p.Asp110Gly | p.D110G | Q96HD9 | protein_coding | deleterious(0) | benign(0.287) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ACY3 | SNV | Missense_Mutation | novel | c.97N>T | p.His33Tyr | p.H33Y | Q96HD9 | protein_coding | tolerated(0.21) | benign(0.001) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACY3 | SNV | Missense_Mutation | c.362N>G | p.Asn121Ser | p.N121S | Q96HD9 | protein_coding | deleterious(0.03) | benign(0.013) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ACY3 | SNV | Missense_Mutation | c.797G>A | p.Ser266Asn | p.S266N | Q96HD9 | protein_coding | tolerated(0.18) | benign(0.005) | TCGA-AP-A0LT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 91703 | ACY3 | NA | atenolol | ATENOLOL | 28353407 | |
| 91703 | ACY3 | NA | bisoprolol | BISOPROLOL | 28353407 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |